Eurofins Scientific SE
ERFSF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.24 | -0.68 | -0.95 | 0.67 |
| FCF Yield | 8.19% | 3.33% | 3.66% | 4.63% |
| EV / EBITDA | 9.26 | 13.76 | 11.72 | 15.33 |
| Quality | ||||
| ROIC | 5.74% | 9.62% | 12.62% | 12.09% |
| Gross Margin | 67.79% | 21.10% | 66.82% | 68.00% |
| Cash Conversion Ratio | 2.38 | 3.28 | 1.46 | 1.43 |
| Growth | ||||
| Revenue 3-Year CAGR | 1.17% | -1.02% | 7.26% | 13.76% |
| Free Cash Flow Growth | 68.98% | -1.74% | -51.92% | 14.09% |
| Safety | ||||
| Net Debt / EBITDA | 2.19 | 2.22 | 2.10 | 1.45 |
| Interest Coverage | 4.82 | 9.57 | 13.11 | 13.27 |
| Efficiency | ||||
| Inventory Turnover | 15.78 | 36.98 | 15.30 | 13.94 |
| Cash Conversion Cycle | -3.03 | 63.13 | 39.89 | 46.84 |